DLL3 and cancer: The transcripts were selected to inform about diverse resistance mechanisms (AR-V7 expression, neuroendocrine transdifferentiation), druggable targets and predictive markers (PSMA, DLL3, SLFN11), and cancer-related processes such as epithelial mesenchymal transition (VIM, KRT).